meropenem
Selected indexed studies
- Meropenem use and therapeutic drug monitoring in clinical practice: a literature review. (J Clin Pharm Ther, 2021) [PMID:33533509]
- Meropenem clinical pharmacokinetics. (Clin Pharmacokinet, 1995) [PMID:7648757]
- Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination. (Ann Pharmacother, 2018) [PMID:29514462]
_Worker-drafted node — pending editorial review._
Connections
meropenem is a side effect of
Sources
- Ertapenem Versus Meropenem for the Treatment of Extended Spectrum Beta-Lactamase-Producing Enterobacterales Bacteremia in Critically Ill Patients. (2024) pubmed
- Comparative review of imipenem/cilastatin versus meropenem. (2020) pubmed
- Meropenem use and therapeutic drug monitoring in clinical practice: a literature review. (2021) pubmed
- Meropenem clinical pharmacokinetics. (1995) pubmed
- Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination. (2018) pubmed
- Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections. (2018) pubmed
- Optimizing meropenem therapy in critical infections: a review of pharmacokinetics/pharmacodynamics research and clinical practice. (2025) pubmed
- Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae. (2018) pubmed
- New evidence in severe pneumonia: meropenem-vaborbactam. (2022) pubmed
- Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections. (2019) pubmed